We are live on ! Find out more
BCDA icon

BioCardia
BCDA

25 hedge funds and large institutions have $4.87M invested in BioCardia in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,766% more capital inflows, than outflows

Capital inflows: $1.45M | Capital outflows: $77.8K

101% more call options, than puts

Call options by funds: $597K | Put options by funds: $297K

9% more funds holding

Funds holding: 23 → 25 (+2)

3.87% more ownership

Funds ownership: 9.21% → 13.08% (+3.9%)

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

Holders
25
Holders Change
+2
Holders Change %
+8.7%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
6
Closed
–
Calls
$597K
Puts
$297K
Net Calls
+$300K
Net Calls Change
-$92K

Top Buyers

Rank Fund Capital Flow
1
ACM
AIGH Capital Management
Maryland
+$1.13M
2
Worth Venture Partners
Worth Venture Partners
New Jersey
+$278K
3
Citadel Advisors
Citadel Advisors
Florida
+$22K
4
UBS Group
UBS Group
Switzerland
+$11.5K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$7.42K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$46.3K
2
Millennium Management
Millennium Management
New York
-$19K
3
Osaic Holdings
Osaic Holdings
Arizona
-$9.47K
4
Tower Research Capital (TRC)
Tower Research Capital (TRC)
New York
-$2.47K
5
Renaissance Technologies
Renaissance Technologies
New York
-$370

BCDA Hedge Fund Activity: Q4 2022 in Review

25 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in BioCardia (BCDA) for Q4 2022, worth a combined $4.87M — up 54% from $3.17M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BCDA positions and 0 closed out — a net gain of 3 holders — while 6 added to existing stakes and 6 trimmed.

The largest buyer was AIGH Capital Management, opening a new position worth an estimated $1.13M. The largest seller was Susquehanna International Group, cutting an estimated $46.3K.

  • 25 institutional investors held BioCardia (BCDA) as of Q4 2022, up from 23 in Q3 2022.
  • Funds reported $4.87M of BioCardia stock for Q4 2022, up 54% quarter-over-quarter.
  • 3 funds opened new BioCardia positions in Q4 2022 and 0 closed out, a net change of +3 holders.
  • The largest BioCardia buyer in Q4 2022 was AIGH Capital Management, an estimated $1.13M added.
  • The largest BioCardia seller in Q4 2022 was Susquehanna International Group, an estimated $46.3K sold.

Based on aggregated 13F filings for Q4 2022.